EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.

Jianlin Xu,Bo Jin,Tianqing Chu,Xue Dong,Haitang Yang,Yanwei Zhang,Dan Wu,Yuqing Lou,Xueyan Zhang,Huiming Wang,Baohui Han

Lung Cancer（2016）

引用 77|浏览8

暂无评分

摘要

•Retrospectively identified patients with uncommon EGFR mutaions.•TKI is effective in L861Q/G719X/Del-19+L858R/Del-19 or L858R+others rare mutations.•TKI is less effective in 20ins/Del-19 or L858R+T790M.

查看译文

关键词

Lung cancer,Non-small cell lung cancer,EGFR,Mutations,Tyrosine kinase inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要